Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  irinotecan hydrochloride
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 236 for your search:
Start Over
Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2012-03, NCT01564810
Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: CTONG1404, NCT02348450
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: IRB14-0594, NCI-2014-02574, P30CA014599, NCT02366819
Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer
Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 18 to 74
Sponsor: Other
Protocol IDs: DREAM-002, NCT02401971
A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: Haema CBF SCLC UK/AS 01, NCT00168896
A Phase II Study of Irinotecan in 3 Line or More Therapy in Local Recurrence or Metastatic Breast Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: STao, NCT02030678
Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NEPAFOX, NCT02172976
Induction Chemotherapy, FOLFIRINOX Followed With Concurrent Capecitabine and Radiation Therapy in Inoperable Locally Advanced Cancer of the Pancreas
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: LAP001, NCT02311439
Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 75 and under
Sponsor: Other
Protocol IDs: FFCD 2000 – 05, CET 815, NCT00126256
5FU/VL Vs LV5FU2 + CPT11 in Stage II-III Resected Rectal Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: AERO-R98, NCT00189657
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Status: Active
Age: 21 and under
Sponsor: NCI
Protocol IDs: NCI-2011-01975, CDR0000654889, COG-AHEP0731, AHEP0731, U10CA180886, U10CA098543, NCT00980460
Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2007-006254-26, NCT01030042
Efficacy Study of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: KCSG-ST10-01, NCT01224652
Trial of XELIRI/FOLFIRI + Simvastatin Followed by Simvastatin Maintenance in Metastatic Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 19
Sponsor: Other
Protocol IDs: 2009-11-017, NCT01238094
Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: ML22011, NCT01249638
Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: CPP-450, 2010-019140-39, NCT01317433
Irinotecan/Capecitabine Versus Capecitabine in Patients Treated With A/T for HER2 Negative Metastatic Breast Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 20 and over
Sponsor: Other
Protocol IDs: NCCCTS-11-536, NCT01501669
Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 79
Sponsor: Other
Protocol IDs: Prodige 24 / Accord 24, NCT01526135
FOLFIRI or mFOLFOX6 in Adjuvant Chemotherapy in Advanced Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2011-170, NCT01566942
The Role of Surgery of the Primary Tumour With Few or Absent Symptoms in Patients With Synchronous Unresectable Metastases of Colon Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CAIRO4, NCT01606098
Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: DE766-A-J302, NCT01813253
Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2009-014476-21, NCT01827553
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NLG0505, 1210-1195, NCT01836432
Start Over